Cell therapy

#Antibody drug conjugate (ADC) #Cancer immunotherapy #Cancer vaccine #Cell therapy #Immunotherapy

New DDW Highlights podcast: 20 January 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have seen a number of positive announcements related to the early… Read More

#News

#Antibody drug conjugate (ADC) #Cancer immunotherapy #Cancer vaccine #Cell therapy #Immunotherapy

This week in drug discovery (13-17 January) 

News round-up for 13-17 January by DDW Senior Digital Content Editor Diana Spencer. This week we have seen a number of positive announcements related to the early clinical and preclinical development of immunotherapies, including an islet cell therapy for diabetes, an antibody-drug conjugate and a CAR-T therapy for… Read More

#News

CAR-T in multiple myeloma
#CAR-T #Cell therapy #EsoBiotec #In vivo #Myeloma #Pregene Biopharma

In vivo BCMA CAR-T candidate shows promise in first human trial

EsoBiotec and Pregene Biopharma have dosed the first patient in an investigator-initiated clinical trial in China of ESO-T01 for relapsed/refractory multiple myeloma.   ESO-T01 is an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into highly effective BCMA CAR-T cells.  The clinical… Read More

#Cancer Research #News

Pancreatic cells
#allogeneic cell therapies #Cell therapy #Diabetes #Sana Biotechnology #Type 1 diabetes

First evidence of cell transplant without immunosuppression

Positive results have been revealed from the first-in-human study transplanting an islet cell therapy into a patient with type 1 diabetes without the use of immunosuppression.  The study was investigating Sana Biotechnology’s UP421, an allogeneic primary islet cell therapy that has been engineered with… Read More

#News #Trending News

Neurons
#Cell therapy #GPCRs #Neurology #Neuroscience #Stanford University

New ‘PAGER’ technology could transform cell therapies

Researchers at Stanford University have built a new synthetic receptor with broad potential to programme cell activity, including immune response and neurological signalling.  Detailed in a paper published in Nature, the new synthetic receptor accommodates a broader range of inputs and… Read More

#Editor's Choice #News

Gene therapy concept
#Blood cancer #CAR-T #Cell therapy #Regenerative Medicine #Stem cells #Tune Therapeutics

Unlocking the future of medicine with cell therapy

Nathan Yee, Senior Director of CMC Portfolio Strategy at Tune Therapeutics, and Lucas Thompson, Senior Director of Research at Tune Therapeutics, discuss the opportunities and challenges in cell therapy. Cell therapy is a transformative medical approach that harnesses living cells as therapeutic agents and has demonstrated the potential to address… Read More

#Cancer Research #Exclusive Content #Opinion

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy

New DDW Highlights episode: 16 December 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It’s been a big week for cell and gene therapies… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy

This week in drug discovery (9-13 December) 

News round-up for 9-13 December by DDW Senior Digital Content Editor Diana Spencer. It’s been a big week for cell and gene therapies (CGTs) as the first in vivo BCMA CAR-T candidate reaches the clinic and a new discovery could lead to a gene therapy that reverses a… Read More

#News

Blood cancer
#Blood cancer #CAR-T #Cell therapy #Haematology #Oncology #Phase I trial #Synthekine

Positive initial results from trial of CD19 CAR-T in blood cancers

Synthekine has announced positive initial results from a Phase I study of SYNCAR-001 + STK-009 for the treatment of relapsed or refractory CD19+ haematologic malignancies.  In the results presented from eight patients treated in the dose escalation portion of the study with a fixed SYNCAR-001 infusion of… Read More

#Cancer Research #News

CAR-T therapy
#CAR-T #Cell therapy #EsoBiotec #In vivo #Myeloma #Phase I trial

First in vivo BCMA CAR-T candidate reaches the clinic

A clinical trial has launched in China of ESO-T01, an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into BCMA CAR-T cells, for the treatment of multiple myeloma.  The proof-of-concept, first-in-human trial is underway and initial clinical data are expected to be presented… Read More

#Editor's Choice #News

CAR-T cells attacking a cancer cell
#CAR-T #Cell therapy #High throughput screening #Live cell analysis #Oncology #Webinar

Last chance: Optimising expansion conditions for CAR-T cells

The development of gene-modified cell therapies, particularly CAR-T cells, has transformed cancer treatment by offering personalised and potentially curative options. But how can you enhance the characterisation and expansion of CAR-T cells and address ‘on target, off tumour’ effects? Register now for this exclusive… Read More

Webinar date:
Supported by Sartorius
#News

CAR-T cells attack cancer cells
#Autolus #Blood cancer #CAR-T #Cell therapy #Leukaemia #Oncology #University College London

Next-generation therapy overcomes limitations of other CAR-T

A new chimeric antigen receptor T cell (CAR-T) therapy has delivered highly promising results in treating patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL).  The FELIX clinical trial was led by researchers at University College London (UCL) and UCLH and sponsored by UCL spin-out Autolus Therapeutics. Read More

#Cancer Research #Editor's Choice #News

Roche headquarters
#CAR-T #Cell therapy #Mergers and acquisitions #Poseida Therapeutics #Roche

Roche buys CAR-T specialist Poseida Therapeutics for $1.5bn

Roche has entered into a definitive merger agreement to acquire Poseida Therapeutics, a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies.  Roche will acquire the company for $9 per share in cash at closing, representing a total equity value of approximately $1 billion.  Stockholders would also receive a non-tradeable contingent… Read More

#Business & Investment #News #Trending News

Hepatitis B
#Cell therapy #Phase I trial #SCG Cell Therapy #T cell receptor (TCR) #Viral hepatitis

T cell therapy for HBV shows promising antiviral activity

SCG Cell Therapy has announced late-breaking data from its Phase I trial of SCG101, a first-in-class autologous hepatitis B virus (HBV)-specific T-cell receptor-engineered T cell (TCR-T) therapy targeting hepatitis B surface antigen (HBsAg).   The data was presented at the 2024 AASLD Liver Meeting in San Diego, United… Read More

#Editor's Choice #News

CAR-T therapy
#CAR-T #Cell therapy #High throughput screening #Live cell analysis #Oncology #Webinar

Register now: Learn techniques for optimising CAR-T expansion

The development of gene-modified cell therapies, particularly CAR-T cells, has transformed cancer treatment by offering personalised and potentially curative options. But how can you enhance the characterisation and expansion of CAR-T cells and address ‘on target, off tumour’ effects? Register now for this exclusive… Read More

Webinar date:
Supported by Sartorius
#News

T cell therapy in lupus
#Autoimmune disease #Cell therapy #Cullinan Therapeutics #Lupus #Preclinical investigations #T cell engagers

Preclinical data supports T cell engager in autoimmune disease

Positive preclinical data for novel CD19xCD3 T cell engager CLN-978 have supported its potential as a new therapeutic option for autoimmune diseases. Cullinan Therapeutics presented the preclinical results and a study schema for a planned Phase Ib study in patients with moderate to severe systemic lupus… Read More

#News